Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup

Schaich, Markus; Schlenk, Richard F.; Al-Ali, Haifa Kathrin; Döhner, Hartmut; Ganser, Arnold; Heil, Gerhard; Illmer, Thomas; Krahl, Rainer; Krauter, Jürgen; Sauerland, Cristina; Büchner, Thomas; Ehninger, Gerhard

doi:10.3324/haematol.11100

Cited by 45 publications

(46 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the number of patients grafted in both studies was lower than 20 patients, not allowing meaningful conclusions as to the true effect of allo-HSCT in AML with þ 8. Recently, Schaich et al 5 reported a series of 131 AML patients aged under 60 years and exhibiting þ 8 within a non-complex karyotype: the 3-year OS and LFS were 29 and 29%, respectively with no differences between patients with þ 8 as a sole aberration and those with þ 8 and one additional cytogenetic aberration. In the latter study, allo-HSCT carried out in 19 patients was an independent prognostic factor for longer LFS (49% at 3 years vs 23% for patients who underwent autologous transplantation vs 28% for patients who received chemotherapy alone, Po0.05).…”

Section: Discussionmentioning

confidence: 99%

“…4 Alternatively, patients with þ 8 occurring concomitantly with other cytogenetic aberrations seem to have the prognosis conferred by the accompanying cytogenetic abnormality, at least in the favorable prognosis group ((t(8;21), t(15;17), inv (16)) or when it is observed concomitantly to additional 11q23 aberrations. 1,5,6 Currently, data assessing specifically the role of allo-hematopoietic SCT (HSCT) in the setting of AML with þ 8 are still relatively sparse. 5,7 The aim of this multicenter retrospective analysis was to carry out a survey on overall outcomes after allo-HSCT of AML patients harboring þ 8 as a sole chromosomal abnormality or associated with other abnormalities.…”

Section: Introductionmentioning

confidence: 99%

“…1,5,6 Currently, data assessing specifically the role of allo-hematopoietic SCT (HSCT) in the setting of AML with þ 8 are still relatively sparse. 5,7 The aim of this multicenter retrospective analysis was to carry out a survey on overall outcomes after allo-HSCT of AML patients harboring þ 8 as a sole chromosomal abnormality or associated with other abnormalities.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT

Chevallier

Labopin

Nagler

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

The aim of this multicenter retrospective analysis was to carry out a survey of overall outcomes after allohematopoietic SCT of AML patients harboring trisomy 8 (þ 8) as the sole chromosomal abnormality or associated with other abnormalities. We have identified 182 de novo AML patients who underwent allo-hematopoietic SCT between 1990 and 2007 exhibiting isolatedor unknown (n ¼ 1) cytogenetic abnormalities reported to the European Group of Blood and Marrow Transplantation (EBMT). With a median follow-up of 48 months, 5-year non-relapse mortality, relapse rate, leukemia-free survival and OS were 25, 30, 45 and 47%, respectively. In a multivariate analysis, leukemia-free survival rate was improved when patients were female and transplanted in CR with an HLA-identical sibling donor. Five-year leukemia-free survival was 41, 88, 57 and 21% in patients bearing isolated þ 8 or þ 8 and other cytogenetic abnormalities of good, intermediate or poor-risk, respectively. Our retrospective data show that allo-hematopoietic SCT is an effective treatment for AML patients harboring þ 8. The accompanying cytogenetic abnormality to þ 8 seems to influence outcomes of these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT

Chevallier

Labopin

Nagler

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Only presence of 480% positive metaphases carrying the þ 8 was associated with inferior survival. 56 With respect to normal karyotype, the optimal postremission treatment strategy was until recently controversial, 57 but current transplantation strategies rather base the indication to allo-SCT on the results of molecular screening (Table 1). 58 The third 'unfavorable group' includes unbalanced karyotypes with numerical or structural gains or losses of chromosomal material ( Table 2).…”

Section: Cytogeneticsmentioning

confidence: 99%

Interactive diagnostics in the indication to allogeneic SCT in AML

Bacher

Haferlach

Schnittger

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Owing to the heterogeneity of AML, the indication for allogeneic SCT (allo-SCT) requires an exact definition of the individual subentity and risk category. A comprehensive diagnostic approach is needed, which combines cytomorphology, cytogenetics, FISH, molecular genetics and immunophenotyping. Whereas the categorization in three prognostic karyotype groups is well established, rare recurrent aberrations as the unfavorable t(8;16)(p11;p13), inv(3)(q21q26) and t(6;9)(p23;q34) must also be considered. In normal karyotype, PCR analyses reveal prognostically relevant mutations in 485% of cases, and a molecular data set composed of the FLT3-ITD, MLL-PTD, NPM1 and CEBPA mutations was found able to guide the selection of patients for allo-SCT. Some novel markers as the WT1 mutations might further contribute to risk stratification in normal karyotype. The panel of minimal residual disease parameters is being expanded at this time, for example, by quantitative PCR for the NPM1 mutations. Immunophenotyping allows the definition of leukemia-associated phenotypes in nearly all cases, but its position in the indication to allo-SCT has to be validated. Thus, the optimization of the indication to allo-SCT is an ongoing process that should remain in continuous interaction with the increasing panel of known genetic markers and diagnostic methods.

show abstract

“…For example, having more than one normal metaphase cell was shown to contribute to better outcome in AML with monosomy 5/7 [2]. Similarly, having normal metaphase cells in patients with trisomy 8 was associated with better outcome [3][4][5]. The question in AML is whether the normal metaphases represent residual normal hematopoietic cells or a clone with normal karyotype.…”

mentioning

confidence: 99%

The significance of quantifiable residual normal karyotype hematopoietic cells for toxicity and outcome

Vigil¹,

Block²,

Wetzler³

2011

Leukemia & Lymphoma

View full text Add to dashboard Cite

Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup

Cited by 45 publications

References 25 publications

Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT

Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT

Interactive diagnostics in the indication to allogeneic SCT in AML

The significance of quantifiable residual normal karyotype hematopoietic cells for toxicity and outcome

Contact Info

Product

Resources

About